Related Experiment Videos
Novel platelet products, substitutes and alternatives
1Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada. blajchma@mcmaster.ca
Summary
Novel platelet products are being developed to address limitations of conventional transfusions. While pre-clinical studies show promise, extensive clinical trials are needed to ensure safety and efficacy for patients with thrombocytopenia.
Area of Science:
- Transfusion Medicine
- Hematology
- Biotechnology
Background:
- Conventional liquid-stored platelet concentrates have inherent safety and storage limitations.
- Significant drawbacks persist despite advances in processing and storage of allogeneic platelets.
Purpose of the Study:
- To review recent developments in novel platelet products, substitutes, and alternatives.
- To summarize the status of various innovative hemostatic agents under development.
Main Methods:
- Review of current literature on platelet storage, pathogen inactivation, and alternative hemostatic agents.
- Analysis of pre-clinical and early-stage clinical trial data for novel platelet therapeutics.
Main Results:
- Several novel products, including frozen/cold-stored platelets, lyophilized platelets, infusible platelet membranes (IPMs), and RGD-ligand-bearing red cells, show encouraging pre-clinical results.
- Few novel hemostatic agents have progressed to human clinical trials.
- Diverse product development is ongoing, aiding the understanding of hemostatic effectiveness properties.
Conclusions:
- Novel platelet alternatives show promise but require rigorous demonstration of safety and efficacy through clinical trials.
- Extensive pre-clinical and clinical evaluation (Phase I-III) is essential before widespread clinical adoption for thrombocytopenia treatment.